Chronobiological approaches to antiangiogenic photodynamic therapy of tumors: The first experimental evaluation

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 364-366

  Gamaleia, N F ^a   Lisnyak, I A ^a   Shishko, E D ^a   Mamchur, A A ^a   Prokopenko, I V ^a   Kholin, V V ^b  

^a INSTITUTE OF HYDROBIOLOGY   (Ukraine)

^b SME Photonika Plus   (Ukraine)

Author keywords

Antibodies to vascular endothelial growth factor; Chronotherapy; Circadian rhythm; Circadian rhythm guided PDT; Immunoconjugated hematoporphyrin

Indexed keywords

PHOTOSENSITIZING AGENT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER TISSUE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIODE LASER; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; LEWIS CARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RED LIGHT; SARCOMA; SPECTROFLUOROMETRY;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CHRONOTHERAPY; CIRCADIAN RHYTHM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOPORPHYRINS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872386108     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jiang FN, Richter AM, Jain AK, et al. Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A 549 - tumor-bearing nude mice. Biotechnol Ther 1993; 4: 43-61. (Pubitemid 23226255)
2. Savellano M, Pogue B, Hoopes P, et al. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpessing cancer cells with pyropheophorbide - immunoconjugates. Cancer Res 2005; 65: 6371-79. (Pubitemid 40994424)
3. Koyanagi S, Kuramoto Y, Nakagawa H, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 2003; 63: 7277-83. (Pubitemid 37413468)
4. Gamaleia NF, Lisnyak IO, Novichenko NL, et al . Synthesis and experimental evaluation of the new antibody-conjugated sensitizer for photodynamic therapy of tumors. Photomed Photobiol 2007; 5: 76-82.
5. Lisnyak IO, Novichenko NL, Mamchur AA, et al . Photoactive immunoconjugate of hematoporphyrin with antibodies to vascular endothelial growth factor: preparation, physicochemical and biological properties. Biopolym Cells 2009; 25: 56-61.
6. Lisnyak IO. Angiogenic factor from metastasizing tumor Lewis carcinoma. Ukr Biochem J 1986; 6: 58-61.
7. Mew D, Wat CK, Towers EH, et al. Photoimmunotherapy treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 1983; 130: 1473-7. (Pubitemid 13159902)
8. Altinok A, Lévi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci 2009; 36: 20-38.
9. Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev 2010; 62: 979-1001.
10. Lévi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv 2011; 8: 1535-41.
11. Method of photodynamic treatment of malignant tumors. Patent UA No 9863. Publ date 10.05.2012.